Novo Nordisk must stay ready to increase Wegovy sales, says CFO

Serious production difficulties in the US mean that Novo Nordisk wil only receive limited amounts of obesity drug Wegovy over the next six months. However, the company promises that its salespeople are chomping at the bit to get going as soon as the problems are solved.
Group CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR
Group CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR
by marketwire, translated by catherine brett

Novo Nordisk's latest issue with meeting patient demand for obesity drug Wegovy arose just one week after its sales force were called to a meeting in Las Vegas to prepare a large-scale sales campaign.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading